CCK-1 receptor blockade for treatment of biliary colic: a pilot study.

Abstract

BACKGROUND:

Loxiglumide is a potent and selective cholecystokinin-1 (CCK-1) receptor antagonist able to inhibit gall-bladder contraction.

AIM:

To assess the effect of CCK-1 receptor blockade on the pain of patients with biliary colic.

PATIENTS AND METHODS:

Fourteen patients with biliary colic but no suspicion for acute cholecystitis, were randomly and blindly assigned to loxiglumide (50 mg i.v.) or hyoscine-N-butyl bromide (20 mg i.v.) treatment. Pain intensity was monitored by a Visual Analogue Scale. Patients with less than 80% response at 30 min, were retreated with a second injection of the same compound.

RESULTS:

Reduction in pain score (mean +/- S.E.M.) was faster and significantly greater in patients treated with loxiglumide (n = 7) than in controls (n = 7): 88 +/- 7% vs. 47 +/- 12% after 20 min, P < 0.05; 92 +/- 6% vs. 49 +/- 13%, after 30 min, P < 0.05. Only one of seven patients treated with loxiglumide needed a second injection at 30 min (vs. six of seven controls, P < 0.05). No adverse effect was observed after either treatment.

CONCLUSIONS:

Loxiglumide is highly effective in obtaining pain relief in patients with biliary colic. The analgesic effect of CCK-1 receptor blockade is superior to that of a conventional anticholinergic treatment.

• Authors: A Malesci, R Pezzilli, M D'Amato, L Rovati
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 18 Issue 3 Pg. 333-7 (Aug 01 2003) ISSN: 0269-2813 [Print] England
• PMID: 12895218 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Receptors, Cholecystokinin
• loxiglumide
• Proglumide

Topics

• Adolescent
• Adult
• Aged
• Biliary Tract Diseases (drug therapy)
• Colic (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Pain Measurement
• Pilot Projects
• Proglumide (analogs & derivatives, therapeutic use)
• Receptors, Cholecystokinin (antagonists & inhibitors)